Chin-Hsien Lin, MD, PhD, National Taiwan University, Taipei, Taiwan, gives an overview of the latest advances and ongoing investigations into biomarkers to diagnose and guide the management of Parkinson’s disease (PD). Markers developed to date, predominantly clinical and neuroimaging markers, are limited in their specificity and sensitivity when applied individually. Biofluid and genetic markers appear most promising and have the potential to act objectively to facilitate early diagnosis, detect or predict disease progression, and guide clinical management. Dr Lin highlights specific α-synuclein species in the blood and LRRK2 kinase activity as promising biomarkers under investigation. This interview took place during the 2021 International Congress of Parkinson's Disease and Movement Disorders.
